[1]ChemicalCommunications,2018,vol.54,p.10574-10577
[2]Patent:WO2017/156508,2017,A1.Locationinpatent:Paragraph00281;00282
[1]CurrentPatentAssignee:FOGHORNTHERAPEUTICSINC-WO2020/160180,2020,A1
16717-25-2
1810-66-8
190777-77-6
82827-09-6
33930-63-1
941-91-3
1306761-53-4 | RP 001 hydrochloride | AA00A0KM | MFCD20926349
1415800-38-2 | Bromo-PEG5-t-butyl ester | AA00A15F | MFCD22683304
1346702-54-2 | 6-Bromo-1-isopropyl-1h-indazole-4-carboxylic acid | AA00A1FA | MFCD26407123
1220172-66-6 | N-Benzyl-n-methylpyrrolidin-3-amine | AA00A3WU | MFCD16709668
13325-14-9 | 2-Butanol, 3-aMino-3-Methyl | AA00A5WZ | MFCD19203579
1215295-82-1 | 2,4,5,6-Tetrahydrocyclopenta[c]pyrazol-3-ylmethanol | AA00A9WM | MFCD16140253
1363381-08-1 | 2-Oxa-spiro[3.3]heptan-6-ol | AA00AAST | MFCD20926156
187237-35-0 | 5-AMINOLEVULINIC-2,2-D2 ACID HCL | AA00AB2X | MFCD08704886
193354-13-1 | 5-Iodoindolin-2-one | AA00ABCK | MFCD08669500
167354-41-8 | (2R)-1-{4-[(1aR,6r,10bS)-1,1-Difluoro-1,1a,6,10b-tetrahydrodibenzo[a,e]cyclopropa[c]cyclohepten-6-yl]piperazin-1-yl}-3-(quinolin-5-yloxy)propan-2-ol | AA00ABJD | MFCD09837761